×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| ALIVUS LIFE SCIENCES LIMITED | 6108.31 | 1215.35 | 6018.46 | 9.88 | 11,323 | 22.8 |
| PROCTER & GAMBLE HEALTH LIMITE | 3427.7 | 661.8 | 3387.4 | 39.87 | 10732 | 35.7 |
| HealthCare Global Enterprises | NA | NA | NA | NA | 9630 | 260.0 |
Glenmark Life Sciences Limited, with Security Code 543322, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 621.3 | 578.5 | 595.4 | 572.8 | 536.6 | 588.6 | 506.9 | 641.8 | 649.5 | 601.8 |
| Expenses | 414.9 | 385.3 | 428.3 | 400.2 | 395.2 | 429.1 | 372.5 | 451.5 | 451.1 | 429.5 |
| Operating Profit | 206.4 | 193.2 | 167.1 | 172.6 | 141.4 | 159.5 | 134.4 | 190.3 | 198.5 | 172.3 |
| OPM % | 33.22% | 33.39% | 28.06% | 30.12% | 26.36% | 27.09% | 26.51% | 29.65% | 30.56% | 28.63% |
| Other Income | 2.8 | 1.9 | 5.4 | 1.7 | 3.1 | 5.5 | 8.5 | 10.5 | 10.1 | 9.0 |
| Interest | 0.1 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.5 | 1.3 | 1.3 |
| Depreciation | 11.5 | 12.6 | 13.1 | 13.2 | 14.5 | 14.4 | 15.1 | 15.2 | 16.0 | 17.1 |
| Profit before tax | 197.6 | 182.0 | 158.9 | 160.7 | 129.7 | 150.2 | 127.5 | 185.1 | 191.3 | 163.0 |
| Tax % | -25.9% | -25.6% | -25.3% | -26.1% | -24.5% | 25.8% | 25.2% | 26% | -25.8% | 25.4% |
| Net Profit | 146.4 | 135.5 | 118.7 | 118.8 | 97.9 | 111.5 | 95.3 | 137.0 | 141.9 | 121.5 |
| EPS in Rs | 11.94 | 11.05 | 9.69 | 9.67 | 7.97 | 9.08 | 7.75 | 11.14 | 0 | 9.88 |
No Consolidated data available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 9% |
| 3 Years: | 4% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 37% |
| 1 Year: | 34% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 37% |
| 1 Year: | 34% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|